Is the PSA test recommended for prostate cancer screening?

The PSA test is not recommended for routine prostate cancer screening in the general population.

Most organizations now recommend that anyone considering PSA screening first discuss the risks and benefits with their doctor. The U.S. Preventive Services Task Force says that for people aged 55 to 69 the decision should be an individual one, made after weighing the potential benefits and harms, and that screening is not recommended for those 70 and older. That guidance dates from 2018 and is currently being updated.

Some organizations suggest earlier routine testing for people at higher risk, such as Black men, those with inherited BRCA changes, and those with a father or brother who had prostate cancer. NCI notes those groups may start testing around age 40 to 45. It's a decision to make with your doctor.

Why a simple blood test needs a conversation at all

PSA is prostate-specific antigen, a protein made by the prostate. It is specific to the prostate. It is not specific to cancer. That one distinction drives everything else.

A level above 4.0 ng/mL is generally treated as abnormal and may lead to a biopsy. Doctors sometimes shift that line by age, using 5 ng/mL for older men or 2.5 ng/mL for younger ones.

Plenty of harmless things push the number up. NCI lists benign prostatic hyperplasia, which is age-related enlargement, and prostatitis, an inflamed prostate. A recent biopsy, ejaculation, and hard exercise such as cycling can also raise it for a while.

Some things push it down. Finasteride and dutasteride, taken for prostate enlargement or hair loss, lower PSA. If you take one, your doctor needs to know, because an ordinary-looking number may not be ordinary.

The two harms that shape the guidance

False positives. NCI reports that about 6% to 7% of men have a false-positive PSA on any given round of screening. That usually leads to a biopsy, which carries risks of serious infection, pain, and bleeding.

Overdiagnosis. This is the harder one. Many prostate cancers grow so slowly that they would never have caused a symptom in a man's lifetime. Screening finds them anyway. Treating them can bring urinary, bowel, and sexual side effects that the cancer itself never would have caused.

That is why the recommendation stops at 70. Late in life, the odds that a slow tumor will ever matter drop, while the odds that treatment will cause harm do not.

Making the decision yours

Useful questions to bring to the visit:

• Given my age, health, and family history, what is my actual risk?
• If my PSA comes back high, what happens next, and would I want that?
• Would you use an MRI before going to biopsy?
• If a slow-growing cancer turns up, is active surveillance an option here?

That last one matters. Active surveillance means monitoring a low-risk cancer with repeat testing rather than treating it right away. Knowing it is on the table changes the calculation, because finding a cancer no longer automatically means treating it.

One thing PSA is not for

Screening means testing when you feel fine. If you have symptoms such as trouble urinating, blood in the urine or semen, or new bone pain, that is not screening. Those are reasons to be evaluated, and the guidance above does not apply.